Cryo-EM fo­cused biotech from long­time NIH vet­er­an se­cures $40M back­ing from Bay­er in Se­ries A

“It’s al­ways nice to get mon­ey in the bank.”

That’s what Gan­dee­va Ther­a­peu­tics’ founder and CEO Sri­ram Sub­ra­ma­ni­am said af­ter re­veal­ing that his com­pa­ny land­ed $40 mil­lion in Se­ries A fund­ing. Gan­dee­va will use the mon­ey for its ar­ti­fi­cial in­tel­li­gence-en­abled plat­form to iden­ti­fy small mol­e­cules and bi­o­log­ics at a faster pace.

The com­pa­ny is on a mis­sion to show that it can lever­age cryo-EM and AI to make a mean­ing­ful im­pact on drug dis­cov­ery, and it plans to do so with speed, us­ing AI for ex­per­i­ment pre­dic­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER